Intravitreal triamcinolone acetonide could be a first line medication for patients with DME in a community setting

Authors : Shubhangi T Shevale, G V Narendra, K Srinivasa Rao, V S Gurunadh

DOI : 10.18231/j.ijceo.2020.093

Volume : 6

Issue : 3

Year : 2020

Page No : 433-439

Purpose: Study aims to establish the efficacy and safety of intravitreal triamcinolone injections in the
denovo treatment of DME in a rural poor socio-economic set up.
Materials and Methods: 4 mg Intravitreal injections of 04 mg of triamcinolone acetonide (IVTA) was
given to 50 DME patients as an initial treatment. Best corrected visual acuity (BCVA), central retinal
thickness (CMT) and intraocular pressure (IOP) were analysed before and after the treatment at intervals
of 1 week, 1 month, 3 months and 6 months.
Result: Statistically significant improvements were observed in BCVA, as well as a decrease in CMT after
all time-intervals following IVTA. IOP increases were observed 1 week, 1 and 3 months after IVTA, but
not at 6 months after IVTA. No sight-threatening side effects of IVTA were observed.
Conclusion: IVTA is effective therapeutic measure in control of DME; it could be a therapeutic option of
choice in patients with poor socioeconomic status.

Keywords: Best corrected visual acuity (BCVA), Diabetes mellitus (DM), Diabetic macular oedema (DME), Intravitreal triamcinolone acetonide (IVTA).


Citation Data